BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

VR Laboratories Selects HSG1932 as Lead Development Candidate for Rhinovirus Program


11/30/2012 9:32:49 AM

LEE COUNTY, Fla., Nov. 29, 2012 /PRNewswire-iReach/ -- VR Laboratories LLC today announced they have selected a lead product candidate from their natural product library to target Rhinovirus. Rhinoviruses are the most common cause of acute upper respiratory tract infections (ARTI) or the common cold.

(Photo: http://photos.prnewswire.com/prnh/20121129/CG20924)

The common cold remains a tremendous burden to society with an enormous economic impact. There are an estimated 62 million colds per year in the United States that require therapeutic intervention. An estimated $227 million is spent on antibiotics and $2 billion on nonprescription cough and cold products in the US each year. In addition, 20 million days off work and 22 million days absent from school are attributable to ARTI each year.

HSG1932 is an orally administered and bioavailable product being developed for the relief of cold and flu-like symptoms.

"The common cold remains one of the most prevalent health problems in the world. We identified HSG1932 from our extensive library as our lead candidate to combat this problem based on its ability to inhibit rhinovirus infection in preclinical testing." said Jeff Kottkamp, CEO of VR Laboratories. "We are excited to be moving another leading edge product candidate forward in our growing pipeline of potential natural products targeting major human health problems with significant consumer and societal impact."

About VR Laboratories

VR Laboratories is an innovative natural products company formed by industry professionals in 2010 to be the leading global formulator and producer of natural products. VR Laboratories utilizes industry-changing proprietary technology to create, produce and market "First in Class" condition specific botanical based consumer health and wellness products, FDA-approved botanical pharmaceuticals and medicines, and proprietary ingredients for medicinal and functional foods and beverages. The company utilizes a proprietary technology platform created by HerbalScience, which has fully developed more than 1,000 medicinal and functional ingredients. VR Laboratories is headquartered in Lee County, Florida.

SOURCE VR Laboratories www.vr-laboratories.com

Keywords: VR Laboratories, cold, Jeff Kottkamp, natural, pharmaceuticals, botanical, Rhinovirus

Media Contact:

Jeff Kottkamp, CEO VR Laboratories, LLC, 239-597-9878, Jeffkottkamp@vr-laboratories.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE VR Laboratories



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES